Benzinga | Jan 28, 2022 08:03AM EST

ALX Oncology's Evorpacept Gets Orphan Drug Tag For Gastric Cancer

The FDA has granted Orphan Drug Designation to ALX Oncology Holdings Inc's (NASDAQ:ALXO) evorpacept for gastric cancer and gastroesophageal junction cancer.

* In ASPEN-01, patients with >2L HER2 positive gastric (n=18) treated with evorpacept combined with trastuzumab plus ramucirumab and paclitaxel demonstrated an initial objective response rate of 72.2% with a median duration of response of 14.8 months and a median overall survival of 17.1 months.

* Related content: Benzinga's Full FDA Calendar.

* These results compare favorably with the clinical experience with both ramucirumab plus paclitaxel and trastuzumab-deruxtecan in similar populations.

* Also See: ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation.

* The Company is enrolling ASPEN-06 Phase 2/3 study of evorpacept for advanced HER2 positive gastric cancer.

* Price Action: ALXO shares closed at $14.36 on Thursday